|
KMID : 0880220210590020124
|
|
Journal of Microbiology
2021 Volume.59 No. 2 p.124 ~ p.131
|
|
|
Raloxifene as a treatment option for viral infections
|
|
Hong Su-Bin
Chang Ju-Oae
Jeong Kwi-Wan
Lee Won-Sik
|
|
|
Abstract
|
|
|
|
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene’s mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections.
|
|
|
KEYWORD
|
|
|
raloxifene, drug repositioning, COVID-19, SARS-CoV-2, SERM, estrogen receptor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|